{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-128542","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.200319+00:00","generated_at":"2026-06-07T07:49:44.335411+00:00","sec_items":["1.01","5.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"KALA BIO raises ~$2.0M via private placement of Series F Convertible Preferred Stock","bullets":["Gross proceeds of ~$2.0M from sale of 2,928 Series F Preferred shares at $683.00 per share.","Each Series F Preferred share initially convertible into 100 shares of common, subject to 9.99% beneficial ownership limitation.","Preferred stock ranks senior to common, on parity with Series E, and carries dividend rights equal to as-converted common dividends.","Closing expected on or about December 22, 2023, subject to customary conditions and exemption under Rule 506 of Regulation D.","Company agreed to restrictions on issuing senior/pari passu equity, incurring debt over $1M, or paying dividends without purchaser consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-128542","json":"https://secwatch.observer/filing/0001104659-23-128542.json","markdown":"https://secwatch.observer/filing/0001104659-23-128542.md","text":"https://secwatch.observer/filing/0001104659-23-128542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/0001104659-23-128542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/tm2333579d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:49:44.335411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"477a1c1ffd30c8cb6e7ee7f19900cc56b9d03bfc","claim":"KALA BIO, Inc.: Filed Certificate of Designations for Series F Convertible Non-Redeemable Preferred Stock, establishing rights, preferences, and privileges (effective 2023-12-21).","evidence_excerpt":"On December 21, 2023 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series F Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series F Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/0001104659-23-128542-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"governance_change"},{"claim_id":"64c38a4efaaf7088a0e7de8b9748d8f7eeb979ee","claim":"KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of approximately $2.0 million (effective 2023-12-21).","evidence_excerpt":"On December 21, 2023, KALA BIO, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Preferred Shares”) of Series F Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series F Preferred Stock”), for aggregate gross proceeds of approximately $2.0 million (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465923128542/0001104659-23-128542-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"aggregate gross proceeds of approximately $2.0 million"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}